BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The COVID-19 vaccine duo, Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Pfizer and BioNTech Conclude Late-Stage COVID-19 Trial

Once again, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) are dominating headlines, after the two drugmakers announced their coronavirus vaccine candidate was 95% effective as its final result.

Pfizer, BioNTech Stocks Rise After Final Vaccine Update

Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.

Pfizer says analysis shows 3.8% of participants experienced fatigue

Drugmaker Pfizer said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, and that it would apply for emergency U.S. authorization within days.

Factbox: Development of Pfizer-BioNTech coronavirus vaccine

Pfizer and BioNTech gained in early Wednesday trading after the companies announced their experimental coronavirus vaccine was 95% effective at protecting patients against COVID-19. The updated figure comes from final analysis of trial data. Preliminary results released on November 9 showed the drug to be 90% effective in the nearly 44,000-person trial. The newest information clears the way for Pfizer and BioNTech to apply for emergency-use authorization from the Food and Drug Administration in a matter of days.

Pfizer and BioNTech climb as 95% vaccine effectiveness tees up application for FDA approval

Pfizer Inc. (NYSE: PFE) andBioNTech SE – ADR (NASDAQ: BNTX) have managed to stay ahead in the vaccine race by a hair's breadth. Within days after Moderna Inc (NASDAQ: MRNA) released its first interim analysis, the U.S.-German combo announced results from the final analysis of their late-stage study of their jointly-developed mRNA vaccine, codenamed BNT162b2.

Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety

But don't let your COVID-19 guard down yet. There's still a long way to go before most people will receive the vaccine.

Pfizer COVID-19 vaccine update: Final results shows it's 95% effective, too

The companies said they have collected the two months of safety data on about 19,000 study subjects requested by the U.S. Food and Drug Administration.

Pfizer's COVID-19 vaccine 95% effective in final results, company to seek approval within days

Pfizer puts COVID vaccine effectiveness at 95%; authorization to be sought soon

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

Instant View: Pfizer ends COVID-19 trial with 95% efficacy

It comes after Moderna announced interim data from Phase 3 trials showed its vaccine candidate to be 94.5% effective.

Pfizer-BioNTech Says Covid-19 Vaccine Is 95% Effective, Will Seek Emergency Approval Within Days

Drugmaker Pfizer has provided updated analysis around its COVID-19 vaccine Phase 3 clinical trial data, saying that in the final result of its analysis of the 44,000-participant trial, its COVID-19 vaccine candidate proved 95% percent effective. This is a better efficacy rate than Pfizer reported previously, when it announced a 90% effectiveness metric based on […]

Pfizer says its COVID-19 vaccine is 95% effective in final clinical trial results analysis

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study's primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Dr. Leo Nissola shares what investors need to know about the latest developments in the mRNA vaccine space.

The Motley Fool Sits Down With A Doctor About Pfizer's Coronavirus Vaccine News

Pfizer and BioNTech said final analysis found coronavirus vaccine was 95% effective in preventing Covid-19 and appeared to fend off severe disease.

Pfizer says final data analysis shows Covid vaccine is 95% effective – plans to submit to FDA in 'days'

Pfizer Inc. Chief Executive Albert Bourla said the company and its partner BioNTech SE have passed the minimum two-month follow-up that the U.S. Food and Drug Administration requires as a safety milestone to obtain emergency use authorization for its COVID-19 vaccine candidate, according to media reports. Bourla made the comment at New York Times and STAT summits on Tuesday.

Pfizer CEO says COVID-19 vaccine candidate has passed FDA safety milestone

The Pfizer-BioNTech vaccine has now proved 95% effective in preventing coronavirus and has met the safety criteria needed for emergency authorisation, the firms have said.

Pfizer vaccine 95% effective and will be submitted for authorisation 'within days'

Li Auto Inc.

Pinduoduo Inc - ADR

Pinterest

The earnings season has been mixed. These four stocks to buy reported strong earnings and are likely to be out-performers.

4 Stocks to Buy That Reported Stellar Earnings

Pfizer (PFE) and BioNTech's (BNTX) stocks decline after Moderna COVID-19 vaccine candidate proves 94.5% effective and can be stored at standard refrigerator temperature.

Pfizer (PFE), BioNTech Fall After Moderna COVID-19 Vaccine Data

Moderna

Better Coronavirus Vaccine: Moderna's mRNA-1273 or Pfizer and BioNTech's BNT162b2?

Johnson & Johnson

Coronavirus vaccine race is now at its peak following Moderna's (MRNA) 94.5% effective vaccine in Phase 3 trials. Pfizer (PFE) also bragged about the effectiveness of its vaccine to be more than 90%.

3 Stocks to Win Big as Race for Coronavirus Vaccine Heats Up

As vaccine hype fades, Pfizer and BioNTech are on the cusp of a breakout -- but will they suceed?

2 Top Coronavirus Stocks to Watch in November

Novavax

Investors are worried that Moderna's good news could be bad news for these coronavirus vaccine leaders.

Why Pfizer, BioNTech, and Novavax Stocks Are Sinking Today

Shares of BioNTech SE dropped 5.9% in premarket trading Monday, and Pfizer Inc.'s stock fell 1.7%, after Moderna Inc. said its COVID-19 vaccine candidate can be stored at standard refrigerator temperatures for 30 days, while BioNTech's and Pfizer's vaccine needed to be stored at "ultra-low" temperatures. In addition, Moderna's candidate demonstrated an efficacy rate that may be higher than the BioNTech's and Pfizer's vaccine candidate.

News for BioNTech SE Stock (BNTX)